Small Lymphocytic Lymphoma
📧 Sign up to get email alerts when something new happens for Small Lymphocytic Lymphoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2012-04-11Clinical Trial Update: Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 clinical trial investigating rituximab, pentostatin, cyclophosphamide, and lenalidomide in previously untreated B-cell chronic lymph…
-
FDA approval · 2011-12-21FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
The FDA approves a supplemental application for Revlimid (lenalidomide) submitted by Celgene Corporation, updating regulatory status for the…
-
CLINICAL_TRIALS trial_result · 2011-12-07Clinical Trial Update: Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma [Phase 2]
Phase 2 clinical trial evaluating tipifarnib in relapsed or refractory lymphoma has completed with results posted in 2011.
-
FDA label_change · 2011-10-28FDA Approved: LEUKERAN — Supplemental Application (Waylis Therapeutics LLC)
FDA supplemental application for Leukeran (chlorambucil) submitted by Waylis Therapeutics LLC.
-
CLINICAL_TRIALS trial_result · 2011-06-29Clinical Trial Update: Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies [Phase 2]
Phase II study assessing AT-101 as a single-agent therapy in relapsed or refractory B-cell malignancies has completed, reporting safety and …
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2011-05-03Clinical Trial Update: Arsenic Trioxide in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma [Phase 2]
A Phase 2 clinical trial evaluating arsenic trioxide for relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma …
-
CLINICAL_TRIALS trial_result · 2011-02-21Clinical Trial Update: Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma [Phase 2]
A Phase 2 study evaluating oblimersen sodium in combination with rituximab for recurrent B-cell non-Hodgkin lymphoma completed, with results…
-
CLINICAL_TRIALS trial_result · 2010-12-30Clinical Trial Update: Rituximab and Fludarabine Followed by CAMPATH-1H in Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 2]
Phase 2 trial evaluating Rituximab and Fludarabine followed by alemtuzumab (CAMPATH-1H) in chronic lymphocytic leukemia and small lymphocyti…
-
FDA approval · 2010-10-12FDA Approved: REVLIMID — Supplemental Application (Celgene Corporation)
FDA approved a supplemental application for REVLIMID (lenalidomide) submitted by Celgene Corporation.
-
FDA approval · 2010-02-26FDA Approved: TREANDA — Supplemental Application (Cephalon, LLC)
The FDA approved a supplemental application for TREANDA (bendamustine hydrochloride) from Cephalon, LLC, enabling revisions to its labeling …
-
CLINICAL_TRIALS trial_result · 2008-09-11Clinical Trial Update: Study of Weekly Motexafin Gadolinium (MGd) for Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma [Phase 1, Phase 2]
Phase 1/2 study of weekly motexafin gadolinium (Xcytrin) in chronic lymphocytic leukemia and small lymphocytic lymphoma has completed.
-
CLINICAL_TRIALS trial_result · 2008-06-04Clinical Trial Update: Safety Study of XL844 in Subjects With Chronic Lymphocytic Leukemia [Phase 1]
This clinical trial update reports termination of a Phase 1 safety study of XL844 in patients with Chronic Lymphocytic Leukemia and Small Ly…
-
FDA approval · 2007-10-15FDA Approved: FLUDARABINE — Original Application (Fresenius Kabi USA, LLC)
FDA approved the original application for Fludarabine phosphate (generic fludarabine) from Fresenius Kabi USA, LLC. The approval covers use …
-
CLINICAL_TRIALS research · 2007-04-17Clinical Trial Update: Safety Study of CAT-8015 Immunotoxin in Patients With CLL, PLL or SLL With Advance Disease [Phase 1]
Phase 1 safety study evaluating CAT-8015 immunotoxin in patients with chronic lymphocytic leukemia, prolymphocytic leukemia, or small lympho…